You're absolutely right regarding those points about the...

You're absolutely right regarding those points about the compounds (2256 & 2591) and that the co. has a huge decision to make in terms of the future direction that it takes. There is an accelerating amount of support amongst the scientific community regarding Insulin-like Growth Factors (IGF) and NEU is at the forefront with leading candidate compounds. Also in taking into consideration the US tax bill impacts and likelihood that Pharma will have significant repatriated cash available for acquisitions over the coming years there is a tremendous opportunity to take 2256 to P3 and advance 2591 via a strategic placement to US investors. This would be a win / win situation for the co. giving them another shot at goal plus the chance to fulfill the potential of the 2591 compound. Also there's a huge upside for US funds that come on board by the significantly increased size of the potential market $$$ across the whole spectrum of neurodevelopmental disorders. IMO the co. should focus on the long game and not be looking at a short-term exit deal which would more than likely favour the acquirer.